Theranos Investors Turn Scavengers on Wounded Unicorn’s Remains
- Company disputes ‘simplistic’ narrative of failed technology
- SEC says loan is keeping startup afloat through rest of year
Photographer: Jason Doiy/Getty Images
This article is for subscribers only.
First investors lost billions on Theranos Inc. Now they may end up fighting over the scraps with, of all things, the SEC.
With Silicon Valley still absorbing the dramatic near-collapse of the medical-testing startup once valued at $9 billion, investors are moving to recover what money they can.